Article: Risk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleRisk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients
AuthorsYip, T1
Tse, KC1
Lam, MF1
Tang, S1
Li, FK1
Choy, BY1
Lui, SL1
Chan, TM1
Lai, KN1
Lo, WK1
KeywordsCephalosporin
E coli
Extended-spectrum beta-lactamase
Gastric acid inhibitor
Peritonitis
Issue Date2006
PublisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.com
CitationPeritoneal Dialysis International, 2006, v. 26 n. 2, p. 191-197 [How to Cite?]
Abstract◆ Objective: To determine the risk factors and outcomes of peritonitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in continuous ambulatory peritoneal dialysis (CAPD). ◆ Patients and Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994 to August 2003 were reviewed. Demographic data, underlying medical conditions, recent use of gastric add inhibitors (including H2 antagonist and proton pump inhibitor), recent antibiotic therapy, antibiotic regimen for peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical outcomes were examined. ◆ Results: Over a 10-year study period, 88 episodes of E. coli peritonitis were recorded; 11 of the 88 cases were caused by ESBL-producing E. coli. Recent use of cephalosporins and gastric acid inhibitor were associated with the development of ESBL-producing E. coli peritonitis. Compared with non-ESBL-produdng E. coli peritonitis, more cases in the ESBL-producing E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died of sepsis (27.3% vs 3.9%, p = 0.02). Peritoneal failure rate was higher in the ESBL-producing E. coli group, although the difference was not statistically significant (18.2% vs 3.9%, p = 0.12). ◆ Conclusion: Peritonitis caused by ESBL-producing E. coli is associated with worse clinical outcomes. The use of cephalosporins and gastric acid inhibitors may contribute to its development. Further studies are warranted to investigate and determine the predisposing factors for ESBL-producing E. coli peritonitis. Copyright © 2006 International Society for Peritoneal Dialysis.
ISSN0896-8608
2011 Impact Factor: 2.097
2011 SCImago Journal Rankings: 0.091
ISI Accession Number IDWOS:000237003600013
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorYip, T
dc.contributor.authorTse, KC
dc.contributor.authorLam, MF
dc.contributor.authorTang, S
dc.contributor.authorLi, FK
dc.contributor.authorChoy, BY
dc.contributor.authorLui, SL
dc.contributor.authorChan, TM
dc.contributor.authorLai, KN
dc.contributor.authorLo, WK
dc.date.accessioned2012-09-05T05:25:53Z
dc.date.available2012-09-05T05:25:53Z
dc.date.issued2006
dc.description.abstract◆ Objective: To determine the risk factors and outcomes of peritonitis caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in continuous ambulatory peritoneal dialysis (CAPD). ◆ Patients and Methods: Episodes of E. coli CAPD peritonitis in our unit from October 1994 to August 2003 were reviewed. Demographic data, underlying medical conditions, recent use of gastric add inhibitors (including H2 antagonist and proton pump inhibitor), recent antibiotic therapy, antibiotic regimen for peritonitis episodes, sensitivity test results of the E. coli isolated, and clinical outcomes were examined. ◆ Results: Over a 10-year study period, 88 episodes of E. coli peritonitis were recorded; 11 of the 88 cases were caused by ESBL-producing E. coli. Recent use of cephalosporins and gastric acid inhibitor were associated with the development of ESBL-producing E. coli peritonitis. Compared with non-ESBL-produdng E. coli peritonitis, more cases in the ESBL-producing E. coli group developed treatment failure (45.5% vs 13.0%, p = 0.02) and died of sepsis (27.3% vs 3.9%, p = 0.02). Peritoneal failure rate was higher in the ESBL-producing E. coli group, although the difference was not statistically significant (18.2% vs 3.9%, p = 0.12). ◆ Conclusion: Peritonitis caused by ESBL-producing E. coli is associated with worse clinical outcomes. The use of cephalosporins and gastric acid inhibitors may contribute to its development. Further studies are warranted to investigate and determine the predisposing factors for ESBL-producing E. coli peritonitis. Copyright © 2006 International Society for Peritoneal Dialysis.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationPeritoneal Dialysis International, 2006, v. 26 n. 2, p. 191-197 [How to Cite?]
dc.identifier.epage197
dc.identifier.hkuros117896
dc.identifier.isiWOS:000237003600013
dc.identifier.issn0896-8608
2011 Impact Factor: 2.097
2011 SCImago Journal Rankings: 0.091
dc.identifier.issue2
dc.identifier.pmid16623424
dc.identifier.scopuseid_2-s2.0-33645510764
dc.identifier.spage191
dc.identifier.urihttp://hdl.handle.net/10722/162957
dc.identifier.volume26
dc.languageeng
dc.publisherMultimed, Inc. The Journal's web site is located at http://pdiconnect.com
dc.publisher.placeCanada
dc.relation.ispartofPeritoneal Dialysis International
dc.relation.referencesReferences in Scopus
dc.subject.meshAged
dc.subject.meshEscherichia Coli - Enzymology
dc.subject.meshEscherichia Coli Infections
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPeritoneal Dialysis, Continuous Ambulatory
dc.subject.meshPeritonitis - Microbiology
dc.subject.meshRisk Factors
dc.subject.meshBeta-Lactamases - Biosynthesis
dc.subjectCephalosporin
dc.subjectE coli
dc.subjectExtended-spectrum beta-lactamase
dc.subjectGastric acid inhibitor
dc.subjectPeritonitis
dc.titleRisk factors and outcomes of extended-spectrum beta-lactamase-producing E. coli peritonitis in CAPD patients
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong